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Abstract
Colon cancer is the third most common type of cancer and the second
leading cause of cancer-related death in the western world. Many epidemio-
logical studies have shown that lifestyle and intake of various food compo-
nents influence the colon carcinogenesis. Novel concepts such as nutrigeno-
mics and nutrigenetics which study the interaction between diet and genes
with common goal to optimize health through personalization of diet, pro-
vide approaches to elucidate the complex relationship between nutrients
and genetic polymorphisms involved in various diseases like colon cancer.
Nutrigenetics of colon cancer is based on correlation between folate metab-
olism and polymorphisms in the genes encoding crucial enzymes in folate
metabolism pathway. The folate pathway influences abberant pyrimidine
and purine synthesis as well as the global DNA hypomethylation and
hypermethylation of tumor supressor genes such as APC, hMLH1, p16 and
E-cadherin in colon cancer. In addition, polymorphisms in the MTHFR,
TYMS, MTR, MTRR, RFC, DHFR and other genes involved in the fo-
late pathway have been shown to influence colon carcinogenesis. The cen-
tral role of the folate pathway in the cell has made it a target for a variety of
chemotherapeutics. Polymorphisms in the genes encoding crucial enzymes in
the folate pathway might have an important role in the pharmacogenetics
and nutrigenetics of colon cancer.
INTRODUCTION
Colon cancer is one of the most common types of cancer and one ofthe leading causes of death in the western world, so it is important
to elucidate the influence of various factors on this widespread type of
cancer. It has been observed that environmental and lifestyle factors are
very important in the etiology of colon cancer. Numerous studies have
shown that meat (1), fat (2), fibre and fruit and vegetable consumption
(3) are associated with different development rates of colon cancer. The
specific component of food which may protect against colon cancer is
folate, a water-soluble vitamin B9. Its name was derived from the Greek
word 'folium' which means 'leaf' since it is commonly found in fresh
fruit and vegetables. There are numerous studies linking low folate in-
takes with colon carcinogenesis as well as with the increased risk for
cardiovascular disease, neural tube defects, adverse pregnancy out-
comes and neuropsychiatric disorders. On the other hand, there are nu-
merous evidence for a protective effect of folate supplementation. This
effect on neural tube defects (4) was considered to be sufficient for U.S.
Food and Drug Administration (FDA) to issue a regulation in 1998 re-
quiring that all flour and uncooked cereal grain products in the USA
have to be fortified with folic acid (140µg/100g) (5, 6). Accordingly,
many studies have shown high folate intake to be associated with the
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prevention of colon cancer. In prospective cohort study
performed on 88756 women from the Nurses’ Health
Study, Giovannucci et al. (7) showed that the long term
(over 15 years) use of supplemental folate may substan-
tially reduce the risk of colon cancer for up to 75%. These
and other epidemiology studies have undoubtedly sug-
gested that folate deficiency increases whereas folate sup-
plementation decreases the risk of colon cancer (8, 9).
Personalized medicine and
nutrigenetics
Most genetic variations, such as single nucleotide poly-
morphisms (SNPs), insertions, deletions or repeats have
been determined by sequencing genes encoding en-
zymes related to the disease of interest (10). With se-
quencing of the whole human genome, the knowledge
about genetic variations has increased and yielded novel
concepts such as nutritional genomics which includes
the fields of nutrigenomics and nutrigenetics (11). Nutri-
genomics is the science that examines the response of in-
dividuals to food compounds using modern molecular
biology technologies (e.g. genomics, transcriptomics, pro-
teomics, metabolomics). The long-term aim of nutri-
genomics is to understand how whole body responds to
real foods using an integrated approach termed 'systems
biology' (www.nugo.org). Nutrigenetics, on other hand,
is based on understanding the gene-based differences in
response to dietary components. Nutrigenetics of colon
cancer is based on the correlation between folate metabo-
lism and polymorphisms in the genes encoding crucial
enzymes in the folate metabolism pathway (11, 12, 13).
Folate and colorectal carcinogenesis
In the cell, folate functions as a donor of one-carbon
units and is essential for DNA, RNA and histone meth-
ylation as well as for nucleotide synthesis. Consequently,
low folate status is associated with abberant DNA meth-
ylation which includes global DNA hypomethylation as
well as hypermethylation of CpG promoter sites of tu-
mor suppressor genes such as APC and hMLH1 in colon
cancer (14). APC tumor suppressor gene is inactivated in
at least 90% patients with FAP (familial adenomatous
polyposis) due to germ-line mutations. FAP is an auto-
somal dominant disease in which affected individuals
develop over a thousand benign colorectal adenomas so-
me of which inevitably progress into malignant carcino-
mas. Biallelic inactivation of the gene in familial adeno-
matous polyposis and most sporadic colorectal tumors
promotes tumorigenesis (15). Inactivation of APC tumor
suppresor gene my occur through multiple mechanisms,
including allelic loss, gene mutation or by methylation of
CpG promoter sites. APC promoter hypermethylation
can complete APC loss of function in cases without ap-
parent APC genetic alteration and, as a second hit ac-
cording to Knudson’s two-hit hypothesis for tumor sup-
pressor gene inactivation, in tumors with a one hit in one
allele. Hypermethylation of promoter, like coding region
mutations of APC appears with equal frequency in both
preinvasive and invasive colon neoplasia which indicate
that methylation plays an important role in the colorectal
tumorigenesis (16).
According to these findings, it has been observed that
MMR (MisMatch Repair) deficiency in sporadic colorec-
tal cancer is frequently the result of epigenetic silencing
of the hMLH1 gene by promoter hypermethylation (17).
Such altered pattern of methylation which causes trans-
criptional loss has also been detected in other tumor sup-
pressor genes such as p16 and E-cadherin, confirming the
role of methylation in malignant progression (18, 19).
In plasma, folate is present in the form of 5-methyl-
tetrahydrofolate (5-Methyl THF) which is a cofactor and
methyl donor for the remethylation of homocysteine to
methionine. The reaction is catalyzed by the enzyme
methionine synthase (MTR) which uses cobalamin (vi-
tamin B12) as a cofactor and by the enzyme methionine
synthase reductase (MTRR). Methionine, an essential
amino acid is then converted to S-adenosyl methionine
(SAM) which functions as an universal methyl donor in
the cell. Aberrant folate status results in promoter-spe-
cific hypermethylation of certain tumor suppressor genes
(14, 20), as well as in global DNA hypomethylation, both
characteristic to colon carcinogenesis. Several studies have
shown that dietary supplementation can lead to changes
in DNA methylation. In a randomized controlled trial of
patients with colorectal adenoma, Pufulete et al. (21)
have reported that supplementation with 400µg folic
acid per day for 10 weeks increased the global DNA
methylation in both leukocytes (+31%) and colonic mu-
cosa (+25%), which suggests that DNA hypomethyla-
tion can be reversed by physiological intakes of folic acid.
Gene polymorphisms in folate pathway
Almost a hundred genes are involved either directly or
indirectly in folate metabolism (Figure1), and certain
single nucleotide polymorphisms (SNPs) that are associ-
ated with colon cancer have been identified (13). It has
been hypothesized that genetic polymorphisms in fo-
late-metabolizing enzymes affect global DNA methyla-
tion and changes in the availability of nucleotides for
DNA synthesis and repair (22).
The intracellular form of folate, 5,10-methylenetetra-
hydrofolate (5,10-Methylene THF) acts as a cofactor in
the reductive methylation of 2’-deoxyuridine 5’-mono-
phosphate (dUMP) to 2'-deoxythymidine-5'-monophos-
phate (dTMP) by thymidylate synthase (TS), which is a
crucial reaction in the formation of thymidine in the cell.
When folates are deficient in the cell, uracil can be mi-
sincorporated in DNA and during the repair by the ura-
cil-glycosylase, chromosomal damage as instabilities in
the form of breaks and translocation can be induced (23,
24). Both aberrant DNA methylation pattern as well as
DNA damage are common in many types of cancer and
accordingly in colon cancer. 5,10-Methylene THF is
converted to 5-Methyl THF by methylenetetrahydro-
folate reductase (MTHFR) encoded by the gene posi-
tioned at 1p36.3. The C>T SNP in position 677 yields a
thermolabile enzyme that has been associated with in-
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creased plasma homocysteine and lowered circulating
plasma folate levels, so that an increase in colon cancer
risk could be expected. This has been confirmed by sev-
eral studies (25, 26, 27) but some studies (28, 29, 30) have
reported the contrary. The MTHFR 677TT variant was
associated with the 20-50% decreased risk of colon cancer
largely in the presence of increased intakes of folate and
other B-vitamins (29, 31). In addition, the risk of colo-
rectal adenoma can be increased when there is low intake
of nutrients involved in one-carbon metabolism (10, 32).
Thus, when folate nutrition is adequate, the risk of ade-
noma or colon cancer is reduced. The inverse associations
observed with the reduced MTHFR activity (MTHFR
677TT genotype) may be associated with accumulation
of substrate for MTHFR, 5,10-Methylene THF, since it
acts as a methyl donor in the reaction of conversion of
dUMP to dTMP by thymidylate synthase (TS) (33). The
promoter of gene for thymidylate synthase (TYMS) con-
tains a variable number tandem repeat (VNTR) of 28bp
which is associated with the altered expression of the
protein. Individuals homozygous for the triple 28bp re-
peat (3R) have been shown to have up to 4-fold higher
expression level of the TS protein compared to double re-
peat (2R) (34). Ulrich et al. (35) have shown in their
study that individuals who showed low MTHFR activity
(MTHFR 677TT genotype) and low TS expression (TSER
2R/2R genotype) were unexpectedly the group at the low-
est risk of colorectal adenoma. The same author suggested
that the availability of 5,10-Methylene THF for a third
pathway, purine synthesis, may be another mechanism
linking folate to colorectal carcinogenesis (12).
Many other genes in folate pathway have been investi-
gated for polymorphisms that may be related to colon
carcinogenesis. Methionine synthase (MTR) catalyzes
the methylation of homocysteine to methionine by using
cobalamin (vitamin B12) as a cofactor. During that reac-
tion MTR may become deactivated but the enzyme
methionine synthase reductase (MTRR) can reactivate it.
Methionine synthase gene (MTR) contains the A›G poly-
morphism at bp 2756 which causes an aminoacid substi-
tution from aspartic acid to glycine at codon 919 (D919G)
(36). The A66G polymorphism in the methionine syn-
thase reductase gene (MTRR) results in the substitution
of isoleucine with methionine at codon 22 (37). Since re-
duced folate carrier (RFC) seems to be the main enzyme
for 5-MeTHF transport into cells, its polymorphism
80G>A could have influence on folate status (38). A 19
bp deletion in the intron 1 of the dihydrofolate reductase
(DHFR) gene was shown to remove a potential Sp1 tran-
scription binding site which affects the transcription of
the DHFR gene (39). Polymorphisms in the MTHFR,
TYMS, MTR, MTRR, RFC, DHFR and other genes in-
volved in the folate pathway have been shown to influ-
ence the colon carcinogenesis via methylation reactions
on DNA, RNA, histones and other proteins, as well as
nucleotide synthesis in the cell (10, 25, 28–30).
CONCLUSION
Folate supplementation can have protective effect
against colon cancer when given prior to the formation of
early lesions. Once preneoplastic lesions are formed, fo-
late enchances tumor growth due to its role in the rapidly
dividing cells that need it for the DNA synthesis. This
central role of folate in the cell has made it a noteworthy
target for the group of chemotherapeutic agents anti-
folates which include 5-FU and methotrexate (MTX)
that are commonly used in the treatment of colon cancer.
It is clear that folate and certain SNPs in the folate path-
way may have a crucial role in the nutrigenetics and
pharmacogenetics of colon cancer.
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Figure 1. Folate pathway (adapted from (12)).
REFERENCES
1. ARMSTRONG B, DOLL R 1975 Environmental factors and cancer
incidence and mortality in different countries, with special reference
to dietary practices. Int J Cancer 15: 617-631
2. PRENTICE R L, SHEPPARD L 1990 Dietary fat and cancer: con-
sistency of the epidemiologic data, and disease prevention that may
follow from a practical reduction in fat consumption. Cancer Causes
Control 1: 81-97
3. BURKITT D P 1971 Epidemiology of cancer of the colon and rec-
tum. Cancer 28: 3-13
4. MRC VITAMIN STUDY RESEARCH GROUP 1991 Prevention
of neural tube defects: results of the Medical Research Council Vita-
min Study. Lancet 338: 131-137
5. U.S.FOOD AND DRUG ADMINISTRATION 1996 Food stan-
dards: amendment of standards of identity for enriched grain prod-
ucts to require addition of folic acid. Final rule. 21 CFR Parts 136,
137, and 139. Fed Regist 61: 8781-8807
6. KIM Y I 2003 Role of folate in colon cancer development and pro-
gression. J Nutr 133(11 Supl 1): 3731S-3739S
7. GIOVANNUCCI E, STAMPFER M J, COLDITZ G A, HUNTER
DJ, FUCHS C, ROSNER B A, SPEIZER F E, WILLETT W C 1998
Multivitamin use, folate, and colon cancer in women in the Nurses’
Health Study. Ann Intern Med 129(7): 517-524
8. KIM Y I 1999 Folate and carcinogenesis: evidence, mechanisms, and
implications. J Nutr Biochem 10: 66-88
9. BAILEY L B, RAMPERSAUD G C, KAUWELL G P 2003 Folic
acid supplements and fortification affect the risk for neural tube de-
fects, vascular disease and cancer: evolving science. J Nutr 133:
1961S-1968S
10. HOULSTON R S, TOMLINSON I P 2001 Polymorphisms and
colorectal tumor risk. Gastroenterology 121: 282-301
11. SUBBIAH M T R 2007 Nutrigenetics and nutraceuticals: the next
wave riding on personalized medicine. Transl Res 149(2): 55-61
12. ULRICH C M 2005 Nutrigenetics in cancer research-folate metabo-
lism and colorectal cancer. J Nutr 135(11): 2698-2702
13. MOLLOY A M 2004 Genetic variation and nutritional require-
ments. World Rev Nutr Diet 93: 153-163
14. BARIOL C, SUTER C, CHEONG K, KU SL, MEAGHER A,
HAWKINS N, WARD R 2003 The relationship between hypo-
methylation and CpG island methylation in colorectal neoplasia.
Am J Pathol 162: 1361-1271
15. POLAKIS P 1997 The adenomatous polyposis coli (APC) tumor
suppressor. Biochim. Biophys. Acta 1332: F127-F147
16. HILTUNEN M O, ALHONEN L, KOISTINAHO J MYÖHÄNEN
S, PÄKKÖNEN M, MARIN S, KOSMA V M, JÄNNE J 1997 Hy-
permethylation of the APC (adenomatous polyposis coli) gene promo-
ter region in human colorectal carcinoma. Int J Cancer 70: 644-648
17. TOYOTA M, ISSA J P 1999 CpG island methylator phenotypes in
aging and cancer. Semin Cancer Biol 9: 349-357
18. HERMAN J G 1999 Hypermethylation of tumor suppressor genes
in cancer. Semin. Cancer Biol 9: 359-367
19. BEVILACQUA R A U, SIMPSON J G 2000 Methylation of the
hMLH1 promoter but no hMLH1 mutations in sporadic gastric carci-
nomas with high-level microsatellite instability. Int J Cancer: 7200-203
20. JONES P A, BAYLIN S B 2002 The fundamental role of epigenetic
events in cancer. Nat Rev Genet 3: 415-428
21. PUFULETE M, AL-GHNANIEM R, KHUSHAL A, APPLEBY
P, HARRIS N, GOUT S, EMERY P W, SANDERS T A 2005 Effect
of folic acid supplementation on genomic DNA methylation in pa-
tients with colorectal adenoma Gut 54: 648-65 3
22. STEMPAK J M, SOHN K J, CHIANG E P, SHANE B, KIM Y I
2005 Cell and stage of transformation-specific effects of folate defi-
ciency on methionine cycle intermediates and DNA methylation in
an in vitro model. Carcinogenesis 26(5): 981-990
23. BLOUNT B C, MACK M M, WEHR C M 1997 Folate deficiency
causes uracil misincorporation into human DNA and chromosome
breakage: implications for cancer and neuronal damage. Proc Natl
Acad Sci USA 94: 3290-3295
24. DUTHIE S J, NARAYANAN S, BRAND G M, PIRIE L, GRANT
G 2002 Impact of folate deficiency on DNA stability. J Nutr 132:
2444S-2449S
25. LEVINE A J, SIEGMUND K D, ERVIN C M 2000 The methylene-
tetrahydrofolate reductase 677C–>T polymorphism and distal col-
orectal adenoma risk. Cancer Epidemiol Biomarkers Prev 9: 657-663
26. CHEN J, GIOVANNUCI E, HANKINSON S E, MA J, WILLETT
W C, SPIEGELMAN D, KELSEY K T, HUNTER D J 1998 A pro-
spective study of methylenetetrahydrofolate reductase and methio-
nine synthase gene polymorphisms, and risk of colorectal adenoma.
Carcinogenesis 19(12): 2129-2132
27. ULVIK A, EVENSEN E T, LIEN E A, HOFF G, VOLLSET S E,
MAJAK B M, UELAND P M 2001 Smoking, folate and methyl-
enetetrahydrofolate reductase status as interactive determinants of
adenomatous and hyperplastic polyps of colorectum. Am J Med
Genet 101: 246-254
28. MA J, STAMPFER M J, GIOVANNUCCI E, ARTIGAS C,
HUNTER D J, FUCHS C, WILLETT W C, SELHUB J,
HENNEKENS C H, ROZEN R 1997 Methylenetetrahydrofolate
reductase polymorphism, dietary interactions, and risk of colorectal
cancer. Cancer Res 57(6): 1098-1102
29. CHEN J, GIOVANNUCCI E, KELSEY K, RIMM E B, STAMP-
FER M J, COLDITZ G A, SPIEGELMAN D, WILLETT W C,
HUNTER D J 1996 A methylenetetrahydrofolate reductase poly-
morphism and the risk of colorectal cancer. Cancer Res 56(21):
4862-4864
30. SLATTERY M L, POTTER J D, SAMOWITZ W, SCHAFFER D,
LEPPERT M 1999 Methylenetetrahydrofolate reductase, diet and
risk of colon cancer. Cancer Epidemiol Biomarkers Prev 8: 513-518
31. LE MARCHAND L, DONLON T, HANKIN J H, KOLONEL L
N, WILKENS L R, SEIFRIED A 2002 B-vitamin intake, metabolic
genes and coloretal cancer risky (United States). Cancer Causes Con-
trol 13: 239-248
32. LITTLE J, SHARP L, DUTHIE S, NARAYANAN S 2003 Colon
cancer and genetic variation in folate metabolism: the clinical bot-
tom line. J Nutr 133: 3758S-3766S
33. CHOI S W, MASON J B 2002 Folate status: effects on pathway of
colorectal carcinogenesis. J Nutr 132: 2413S-2418S
34. HORIE N, AIBA H, OGURO K, HOJO H, TAKEISHI K 1995
Functional analysis and DNA polymorphism of the tandemly re-
peated sequences in the 5’-terminal regulatory region of the human
gene for thymidylate synthase. Cell struct Funct 20: 191-197
35. ULRICH C M, BIGLER J, BOSTICK R, FOSDICK L, POTTER
J D 2002 Thymidylate synthase promoter polymorphism, interac-
tion with folate intake and risk of colorectal adenomas. Cancer Res
62: 3361-3364
36. GUÉANT J L, GUÉANT-RODRIGUEZ R M, BOSCO A G,
BRUNAUD L, ROMANO C, FERR R, ROMANO A, CANDITO
M, NAMOUR B 2003 Genetic determinants of folate and vitamin
B12 metabolism: a common pathway in neural tube defect and
Down syndrome? Clin Chem Lab Med 41(11): 1273-1477
37. VAUGHN J D, BAILEY L B, SHELNUTT K P, VON-CASTEL
DUNWOODY K M, MANEVAL D R, DAVIS S R, QUINLIVAN
E P, GREGORY III J F, THERIAQUE D W, KAUWELL G P A
2004 Methionine synthase reductase 66A›G polymorphism is associ-
ated with increased plasma homocysteine concentration when com-
bined with the homozygous methylenetetrahydrofolate reductase
677C›T variant. J Nutr 134(11): 2985-2990
38. WINKELMAYER W C, EBERLE C, SUNDER-PLASSMANN
G, FÖDINGER M 2003 Effects of the glutamate caroxypeptidase II
(GCP2 1561C>T) and reduced folate carrier (RFC1 80G>A) allelic
variants on folate and total homocysteine levels in kidney transplant
patients. Kidney International 66: 2280-2285
39. JOHNSON W G, STENROOS E S, SPYCHALA J R,
CHATKUPT S, MING S X, BUYSKE S 2004 New 19 bp deletion
polymorphisms in intron-1 of dihydrofolate reductase (DHFR): A
risk factor for spina bifida acting in mothers during pregnancy? Am J
Med Genet 124A: 339-345
54 Period biol, Vol 111, No 1, 2009.
M. Joki} and Sanja Kapitanovi} Nutrigenetics and colon cancer
